Latest news
Iconovo at FDA workshop
Iconovo CEO Dr. Orest Lastow took part in an FDA workshop on the evaluation of new methods for characterizing and demonstrating equivalence of OINDP. The…
Swedish Iconovo signs royalty-backed inhalation contract worth 2.8 million EUR
Iconovo, a Swedish inhalation development company has signed a second major product development and licensing agreement with Intas Pharmaceuticals Ltd.…
Press releases
Apr 24, 2026, 09:00
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
General meeting
Notice
Apr 23, 2026, 16:40
News
IR
Swedish
Regulatory
Listing Regulation
Report
Annual
Apr 14, 2026, 15:40
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
Staff change
Apr 14, 2026, 15:40
News
IR
English
Regulatory
Listing Regulation
Corporate Information
Staff change
Mar 17, 2026, 16:05
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
Other Corporate Information
mfn-ext-nq
mfn-ext-nq-listing
Mar 17, 2026, 16:05
News
IR
English
Regulatory
Listing Regulation
Corporate Information
Other Corporate Information
mfn-ext-nq
mfn-ext-nq-listing
Mar 10, 2026, 08:05
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
Other Corporate Information
mfn-ext-nq
mfn-ext-nq-listing
Mar 10, 2026, 08:05
News
IR
English
Regulatory
Listing Regulation
Corporate Information
Other Corporate Information
mfn-ext-nq
mfn-ext-nq-listing
Mar 02, 2026, 16:20
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
Other Corporate Information
mfn-cus-top-disclaimer
mfn-ext-nq
mfn-ext-nq-listing
Mar 02, 2026, 16:20
News
IR
English
Regulatory
Listing Regulation
Corporate Information
Other Corporate Information
mfn-cus-top-disclaimer
mfn-ext-nq
mfn-ext-nq-listing
Feb 27, 2026, 18:20
News
IR
English
Regulatory
Listing Regulation
Corporate Information
Other Corporate Information
mfn-cus-top-disclaimer
mfn-ext-nq
mfn-ext-nq-listing
Feb 27, 2026, 18:20
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
Other Corporate Information
mfn-cus-top-disclaimer
mfn-ext-nq
mfn-ext-nq-listing
Feb 24, 2026, 20:50
News
IR
Swedish
Corporate Action
Other
mfn-ext-nq
mfn-ext-nq-corporate-action
Feb 24, 2026, 20:50
News
IR
English
Corporate Action
Other
mfn-ext-nq
mfn-ext-nq-corporate-action
Feb 13, 2026, 08:30
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
Other Corporate Information
mfn-cus-top-disclaimer
mfn-ext-nq
mfn-ext-nq-listing
Feb 13, 2026, 08:30
News
IR
English
Regulatory
Listing Regulation
Corporate Information
Other Corporate Information
mfn-cus-top-disclaimer
mfn-ext-nq
mfn-ext-nq-listing
Feb 12, 2026, 14:30
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Action
Prospectus
Feb 12, 2026, 14:30
News
IR
English
Regulatory
Listing Regulation
Corporate Action
Prospectus
Possessing a unique combination
of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.
ICONOVO AB
VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B
POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 62 LUND
Sweden
CONTACT
Phone: +46 46 275 67 77
Director Business Development and Alliances
Måns Österberg
Mail: mans.osterberg@iconovo.se
CEO
Anders Månsson
Mail: anders.mansson@iconovo.se
Press releases
Follow us on Linkedin
